German Health Authorities Warn Against Ashwagandha Supplements Over Safety Risks

Health authorities in Germany and across Europe have warned against taking ashwagandha supplements due to safety concerns. The Federal Institute for Risk Assessment highlighted gaps in research, particularly for vulnerable groups like pregnant women, breastfeeding mothers, and children. Despite its popularity, the supplement’s risks and benefits remain poorly understood. Ashwagandha is often advertised as a natural remedy for stress, sleep problems, and metabolic health. Small studies suggest it might reduce anxiety or improve sleep, but the evidence is inconsistent, with varying doses and weak research designs. Some cell experiments even indicate potential anti-tumour effects from its active compounds, called withanolides. However, no human trials have confirmed these findings.

In Germany, no legal limits exist for ashwagandha dosage, leaving consumers exposed to high and unpredictable amounts. Experts point to Poland’s guidelines, which cap daily intake at 10 mg of withanolides or 3,000 mg of ashwagandha. Yet many products on the German market exceed these thresholds—one supplement contained 6,000 mg of ashwagandha and 15 times the recommended withanolide dose. Testing has also revealed that the actual content can differ from the label by up to 50 percent.

The risks of high doses include nausea, dizziness, skin rashes, and liver damage. In the Netherlands, 12 cases of liver injury have already been linked to ashwagandha use. German regulators currently require only basic registration for dietary supplements, with no mandatory safety or efficacy checks before sale. Without strict dosage rules or pre-market testing, ashwagandha supplements remain a potential health risk. Authorities urge caution, especially for those in high-risk groups. The lack of reliable data means consumers cannot assume the products are safe or effective.